TIOGAMMA® DORI VOSITASINING PERİFERİK DABETİK POLİNEYROPATİYA BELGILARIGA TA'SIRI, SHUNINGDEK QANDLI DIABET VA BOSHQA UGLEVOD ALMASHINUVI BUZILISHLARI BOR BEMORLARNING RUHIY HOLATINI BAHOLASH
##article.subject##:
qandli diabet, diabetik polineyropatiya, MMSE shkalasi, NIS-LL shkalasi, alfalipoik (tioktik) kislota##article.abstract##
Oyoqlarda sezuvchanlikni yo'qotish va mushaklar kuchsizligi belgilari periferik diabetik polinevopatiyaning asosiy belgilaridir. Endokrinologlar va diabetologiya sohasidagi boshqa mutaxassislarning asosiy muammosi diabetning yuqoridagi asoratini erta tashxislash qiyinligidadir. Bundan tashqari, diabetik polineyropatiyani davolash yomon kompensatsiya bilan murakkablashadi, bu esa o'ziga xos bosh miyaning ma'lum buzilishlari tufayli QD bemorlarida kognitiv buzilish bilan bog'liq bo'lishi mumkin.
Библиографические ссылки
Ametov AS, Barinov A., Dyck PJ et al. The sensory symptoms of diabetic polyneuropathy are improved with alpha-lipoic acid: the SYDNEY trial. Diabetes Care 2003;26(3):770–6.
Awad N, Gagnon M, Messier C (2004) The relationship between impaired glucose tolerance, type 2 diabetes, and cognitive function.// J Clin Exp Neuropsychol. 26:1044-1080.
Cabezas-Cerra4. Christen W G., Manson JE, Bubes V, Glynn RJ // Am. J. epidemiol. - 1999. - Vol. 150. - P. 1142-1151
Effects of treatment with the antioxidant-lipoic acid on cardiac autonomic neuropathy in NIDDM patients. (DECAN Study) // Diabetes Care.- 1997.-Vol.20,N.3.-P.369-373.
Esther SC Korf, Lon R. White, Ph Scheltens,et.al. Brain Aging in Very Old Men With Type 2 Diabetes The Honolulu-Asia Aging Study // Diabetes Care 29:2268-2274, 2006.
Gregg EW, Venkat Narayan KM.. Type 2 Diabetes and Cognitive Function: Are Cognitive Impairment and Dementia Complications of Type 2 Diabetes? // Clinical Geriatrics. Volume 08. P. 1070-1389.
Gries FA, Cameron NE, Low PA (eds.) Textbook of diabetic neuropathy. Stuttgart: Thieme, 2003
Reljanovic M., Reichel G., Rett K. et al. Treatment of diabetic polyneuropathy with the antioxidant thioctic acid (alpha-lipoic acid): a two year multicenter randomized double-blind placebo-controlled trial (ALADIN II). Alpha Lipoic Acid in Diabetic Neuropathy. Free Radic Res 1999; 31(3):171–9.
Van den Berg E, Kessels RP, Kappelle LJ, et. al. Type 2 diabetes, cognitive function and dementia: vascular and metabolic determinants. // Drugs Today (Barc). 2006 ;Vol.42(11).P.741-54.
Vinik AI, Mehrabyan A. Diabetic neuropathies. Med Clin North Am 2004; 88(4):947–99.
Ziegler D., Ametov A., Barinov A. et al. Oral treatment with alpha-lipoic acid improves symptomatic diabetic polyneuropathy. The SYDNEY 2 trial. Diabetes Care 2006; 29(11):2365–70.
Ziegler D., Hanefeld M., Ruhnau RJ et al. Treatment of symptomatic diabetic polyneuropathy with the antioxidant alphalipoic acid: a 7-month multicenter randomized controlled trial (ALADIN III Study). ALADIN III Study Group. Alpha Lipoic Acid in Diabetic Neuropathy. Diabetes Care 1999;22(8):1296–301.
Ziegler D., Nowak H., Kempler P. et al. Treatment of symptomatic diabetic polyneuropathy with the antioxidant alphalipoic acid: a meta-analysis. Diabet Med 2004;21(2):114–21.
Galstyan G.R., Antsiferov M.B. Treatment of distal diabetic polyneuropathy. // Russian Medical Journal. -2000.-N.4.-pp.201-203.to J. // Diabetologia. - 1998. - Vol. 41. - P. 1263-1269.
